166:
delivery system provides the possibility to target areas of inflammation, increase drug efficacy, and minimize damage to the surrounding tissue. Moreover, because this concentration gradient is ubiquitous in the microenvironment of inflammatory diseases, common drug-targeting limitations such as individual differences can be avoided. Another example of an innovative drug delivery system that uses the property of chemotaxis is leukocytes. Indeed, during inflammation, the molecules on a cell that allows for adhesion are overly produced. With this unique condition, researchers can modify leukocytes to quickly detect the cell, attach itself to the surface, and deliver a therapeutic payload. Overall, many promising therapies and drug delivery systems are being developed to target inflammation more effectively. Chemotactic drug delivery systems are just one of many promising avenues that seek to increase target sites specifically, decreasing the needed drug dosage, reducing toxicity, and increasing drug efficacy.
100:
that of mesoporous silica nanoparticles. These advantages include but are not limited to stability, large capacity for various cargos, low toxicity, immunogenicity, and the ability to circulate the blood for long periods. Thus, researchers aim to create a tunable chemotactic protocell that can move towards or away from a chemical signal. In fact, researchers have devised a way to use the enzymes catalase, urease, and ATPase to move the protocell closer or further away from the reactant, giving them direction and movement control of these protocells. Overall, the development of chemotactic controlled protocols holds great promise for the targeted delivery of drugs to specific areas of the body, potentially increasing treatment efficacy while minimizing side effects. However, more research is needed to fully understand the capabilities and limitations of protocells as drug delivery systems and optimize their design and functionality for specific applications.
150:
approaches. Yet, even these treatments have their own advantages and disadvantages. Thus, since the discovery of cancer, researchers have constantly been developing new and innovative cancer treatments, including chemotactic drug delivery. For example, and as mentioned earlier in this article, researchers have sought to use microdroplets, protocells, and biological and bio-hybrid drug carriers to deliver drugs to cancer cells in a more effective manner, while reducing unwanted side effects. In fact, the justification for using such systems, guided by chemotaxis, is that the environment inside a tumor has a higher resting temperature, higher peroxide concentration, lower pH, and a lower oxygen concentration than its surrounding tissue. With these unique conditions, researchers can exploit chemotactic drug delivery to target tumor cells directly, avoiding healthy tissues, reducing toxicity, improving drug efficacy, and decreasing drug dosage.
91:
can control the time it takes to release a therapeutic payload. Thus, by using the natural process of chemotaxis, researchers aim to guide these tiny droplets by using chemical gradients released by a specific cell, tissue, or organ within the body. In fact, a few examples of microdroplet systems that use chemotaxis are self-propelling, ionic liquid-based, and synthetic base. These microdroplet-based drug delivery systems offer several advantages over traditional drug delivery methods, which are talked about later in the advantage and limitations subsection of this article. Overall, the development of microdroplet-based drug delivery systems using the phenomenon of chemotaxis is just one of may avenues to potentially revolutionize the field of medicine and targeted drug delivery.
128:
cell undergoes inflammation. This secretion of chemoattractants naturally attracts leukocytes, such as macrophages, to the T cell location. Thus, with their well-known chemotactic homing behavior to inflammation or pathogens' sites in mind, researchers can manipulate leukocytes to carry and deliver a therapeutic payload to the tumor site. However, this is not to say that
Biological and bio-hybrid drug carriers do not have challenges and limitations of their own. For example, Leukocytes cannot penetrate deeply into the tumors, have a low capacity for carrying drugs, and slow down when the tumor size reduces. Thus, similar to bacteria drug carriers, further research and development are still needed to address their limitations and improve the overall drug delivery system.
263:
healthy tissue. Moreover, by delivering the drug directly to the desired target, researchers can effectively reduce the required drug dosage needed. However, some limitations to chemotactic drug targeting include issues with biocompatibility, drug-carrying capacity, and the life span of specific carriers. Another major challenge with this approach is motility, when either the chemical stimuli diminish, or the attached enzymes become oversaturated. This can limit the effectiveness of the drug delivery system and may require additional modifications to improve its performance. Thus, although these approaches have shown great promise, more research is still needed to fully understand chemotaxis mechanisms and optimize this property for targeted drug delivery strategies.
222:
systems to meet specific clinical needs. In fact, without modularity and versatility, it will be hard to tailor protocells to different therapeutic applications and particular populations. Another critical challenge, especially when using enzymes to maneuver the protocell, is that the motility reduces when the enzymes become oversaturated with the chemical stimuli. Reducing motility becomes a problem because this is essential for targeted drug delivery efficiency, limiting the system's effectiveness and increasing the risk of off-target effects. Therefore, further research is still needed to improve our understanding of protocells and their potential clinical applications.
213:
effects and toxicity. In like manner, controlling the direction and movement of a drug also reduces the amount of medication needed, increases the speed of delivery, and allows for the controlled release of high-concentration multicomponent cargo within cancer cells. Finally, the stability of protocells is vital because it ensures that the drugs remain effective and do not degrade before reaching their target. Overall, the development of protocells as a drug delivery system, coupled with chemotactic properties, holds great promise for targeted drug delivery.
238:
to inflammation and tumor sites. This natural property of homing to inflammation and tumor sites can enhance the targeted delivery of drugs, minimizing the risk of off-target effects and reducing the required dosage. Additionally, these systems have the potential to increase drug stability and prolong circulation time in the body, improving drug efficacy and reducing the frequency of dosing. Overall, these advantages make biological and bio-hybrid drug carriers promising for developing more effective and targeted drug delivery systems.
24:
dosage needed. The general components of the conjugates are designed as follows: (i) carrier – regularly possessing promoter effect also on internalization into the cell; (ii) chemotactically active ligands acting on the target cells; (iii) drug to be delivered in a selective way and (iv) spacer sequence which joins drug molecule to the carrier and due to it enzyme labile moiety makes possible the intracellular compartment specific release of the drug. Careful selection of chemotactic component of the ligand not only the
197:
overall efficacy, causing unwanted side effects and possibly death. On the other hand, scalability is another crucial challenge to consider because this aspect can lead to increased manufacturing costs, problems with quality control, and limitations in equipment used. All in all, even with great promise to revolutionize targeted drug delivery, researchers must keep in mind the biocompatibility, toxicity, and scalability of microdroplet-based drug delivery systems when using them.
247:
adverse side effects and the cost of the treatment. Moreover, the short lifespan can limit their potential use for long-term drug delivery applications . Coupling this aspect with an inability to penetrate deep into tumors and the potential for genetic mutations can pose significant challenges for future drug delivery systems. Therefore, despite their advantages, further research and development are needed to address current limitations and improve their clinical feasibility.
188:
process and can be varied in porosity to control the time it takes to release a drug. Microdroplets-based drug delivery also has a significant advantage over traditional systems in that they can minimize side effects, reduce the need for invasive procedures, and even improve a drug's efficacy. Overall, microdroplet-based drug delivery systems show great promise for revolutionizing medicine with significant potential for targeted drug delivery.
69:, a medical technique aimed at delivering drugs to a specific cell, tissue, or organ within the body while minimizing its disruptive effects on healthy tissue. By using both chemotaxes to help guide the drug delivery process, researchers aim to reduce toxicity by avoiding healthy tissues, improve drug efficacy by focusing only on the intended site, and decrease drug dosage by delivering the directly rather than throughout the whole body.
37:
259:
their environment. By applying this technique to targeted drug delivery, researchers aim to create drugs that can precisely reach their intended targets, minimizing the potential for side effects, improving drug efficacy, and decreasing drug dosage. Some examples include but are not limited to microdroplets, protocells, biological and bio-hybrid drug carriers, leukocytes, and neutrophils.
120:. Indeed, thanks to their natural chemotactic sensing property, bacteria can be used to locate a tumor, carry a therapeutic payload to the site, and release that drug in a controlled manner. Researchers can also genetically modify these bacteria to produce a specific protein like anti-tumor cytotoxins for cancer treatment.
196:
Nevertheless, it is essential to note some common challenges associated with microdroplet-based drug delivery systems, including their biocompatibility, toxicity, and scalability. The biocompatibility and toxicity of
Microdroplets are essential to consider because these can affect a drug's safety and
127:
Another example of bio-hybrid drug carriers is human cells, like macrophages, which offer compatibility with the human immune system and a simple way to load drugs as a bio-hybrid drug carrier. Leukocytes demonstrate great promise because Tumor cells secrete large amounts of chemoattractants when the
32:
ligands are also valuable as they are useful to keep away cell populations degrading the conjugate containing the drug. In a larger sense, chemotactic drug-targeting has the potential to improve cancer, inflammation, and arthritis treatment by taking advantage of the difference in environment between
23:
called chemotactic drug targeting. By using chemical agents to help guide a drug carrier to a specific location within the body, this innovative approach seeks to improve precision and control during the drug delivery process, decrease the risk of toxicity, and potentially lower the required medical
237:
Some advantages to
Biological and bio-hybrid drug carriers include but are not limited to offering compatibility with the human immune system, having the potential to be genetically modified, and having the capacity to hold drugs. Moreover, an essential advantage is their natural property of homing
174:
While this emerging field of drug delivery shows excellent promise in targeting specific cells and locations within the body, understanding current challenges and drawbacks can allow researchers to optimize design, development, and delivery to improve the overall outcome of their medical treatment.
165:
One promising drug delivery system was based on engineered neutrophils that targeted inflammation sites through chemotaxis's unique properties. This approach took advantage of the concentration difference between iNOS and ROS for inflammatory disease sites and normal tissues. By doing so, this drug
187:
By using uniform droplets to deliver therapeutic payloads to specific locations in the body, researchers can achieve greater precision and control over drug delivery while also minimizing toxicity and harmful side effects. For example, these droplets can be quickly loaded during the polymerization
123:
Yet, this is not to say that they don't come with their own set of challenges and limitations. For one, the genetic modifications of the bacteria used can be manipulated by recent or unforeseen mutations, leading to a decrease in the efficacy of the drug and drug carrier. Moreover, the therapeutic
99:
Another drug delivery system that has shown potential for chemotactic applicability is protocells. In general, protocells are artificial cells that mimic living cells but cannot reproduce and have genetic mutations like living cells do. Moreover, protocells combine the advantages of liposomes with
90:
has led to the development of microdroplets, a new drug-delivery system that uses uniform droplets to deliver drugs to specific locations within the body. These microdroplets allow researchers to load drugs during the polymerization step of their formation and provide variations in porosity, which
55:
is a biological process where living entities, such as cells or organisms, detect, maneuver, and react in response to a chemical signal in their environment. Such a phenomenon is critical for many biological processes, including but not limited to wound healing, detection of food, and avoidance of
246:
One limitation of
Biological and bio-hybrid drug carriers, especially leukocytes, is that they have a low drug-carrying capacity. A limit in the carrying capacity of a carrier means that researchers will have to use more medication to achieve the desired therapeutic effect, increasing the risk of
64:
are specialized sensory cells called chemoreceptors. These cells allow an organism to detect chemical molecules within its environment and respond accordingly. Such chemical molecules are either known as chemoattractants or chemorepellents, which play a crucial role in attracting or repelling the
1549:
258:
Generally speaking, chemotactic drug-targeting is a drug delivery strategy with promising avenues for treating diseases such as cancer and inflammation. This approach mimics the biological process of chemotaxis, which biological organisms use to detect, maneuver, and react to chemical signals in
221:
One fundamental limitation of protocells is their modularity and versatility, which must be accounted for when assessing clinical applications. Modularity and versatility are essential considerations for targeted drug delivery because they enable the customization and adaptation of drug delivery
149:
Cancer is not just one disease but a group of diseases involving abnormal cell growth and metastasis of such cells to other body parts. There are also several types of cancers, each with its own distinctive characteristics and stages that may require different treatment or targeted drug delivery
262:
While chemotactic drug targeting holds great promise for drug delivery, there are key advantages and limitations that must be considered. One main advantage is that these systems can precisely target specific cells, tissues, or organs within the body while minimizing their disruptive effects on
212:
At large, protocells are advantageous because they can store more drugs, be loaded faster than other nanomedicine delivery systems, and are more stable than liposomes. By keeping more drugs, researchers can reduce the quantity of medications needed to be administered, potentially reducing side
77:
Chemotactic drug delivery systems are an emerging field of drug delivery that aims to apply the natural phenomenon of chemotaxis in guiding and delivering a drug to a specific tissue or cell within the body. Thus, similar to how organisms use chemotaxis, researchers have designed drug delivery
1109:
161:
is the body's response to foreign objects, irritants, germs, and even pathogens. Although such a response is standard in some cases, if left untreated, chronic inflammation can lead to muscle degeneration, gastrointestinal disorders, and some types of cancers. While most treatments, such as
1483:
Ashley, Carlee E.; Carnes, Eric C.; Phillips, Genevieve K.; Padilla, David; Durfee, Paul N.; Brown, Page A.; Hanna, Tracey N.; Liu, Juewen; Phillips, Brandy; Carter, Mark B.; Carroll, Nick J.; Jiang, Xingmao; Dunphy, Darren R.; Willman, Cheryl L.; Petsev, Dimiter N. (May 2011).
124:
proteins produced may have incomplete protein folding, decreasing the drug's effectiveness or causing unforeseen side effects. Generally speaking, using bacteria may provide some advantages, but further research and development are still needed to address their limitations.
162:
anti-inflammatory drugs and steroid injections, can help relieve symptoms, they often fail to address the condition's underlying cause. Therefore, researchers have sought to explore new and innovative ways of inflammation treatment, such as chemotactic drug delivery.
140:
therapy, wound healing, and inflammation. The ability to target specific cells and locations within the body through chemical cues has opened up new avenues for the field of drug delivery, allowing for increased drug efficacy and reducing harmful side effects.
33:
the target site and its surroundings. Therefore, this
Knowledge article aims to provide a brief overview of chemotactic drug targeting, the principles behind the approach, possible limitations and advantages, and its application to cancer and inflammation.
112:
or cells to help design drug delivery systems that mimic their surface, shape, texture, and movement. One phenomenon that has become increasingly popular in improving the movement and release of
65:
organism towards or away from the source of the chemical signal, respectively. Thus, with this natural process of chemotaxis in mind, researchers have sought to apply the same phenomenon to
60:
also plays an essential role in several diseases, such as tumor metastasis, the recruitment of T-lymphocytes during inflammation, and HIV-1 entry into T cells. At the core of
19:
is one of many ways researchers seek to improve drug delivery systems' overall efficacy, safety, and delivery. Within this medical field is a special reversal form of
1171:
955:
Theberge, Ashleigh B.; Courtois, Fabienne; Schaerli, Yolanda; Fischlechner, Martin; Abell, Chris; Hollfelder, Florian; Huck, Wilhelm T. S. (9 August 2010).
108:
Finally, biological and bio-hybrid drug carriers have shown potential for chemotactic applications. In general, these systems are inspired by
715:
Damsker, Jesse M.; Okwumabua, Ifeanyi; Pushkarsky, Tatiana; Arora, Kamalpreet; Bukrinsky, Michael I.; Constant, Stephanie L. (January 2009).
660:
Li, Ting; Liu, Zhiyong; Hu, Jinglei; Chen, Lin; Chen, Tiantian; Tang, Qianqian; Yu, Bixia; Zhao, Bo; Mao, Chun; Wan, Mimi (November 2022).
1277:
Li Jeon, Noo; Baskaran, Harihara; Dertinger, Stephan K. W.; Whitesides, George M.; Van De Water, Livingston; Toner, Mehmet (2002).
36:
1199:
1661:
1078:
1651:
78:
systems to detect, maneuver, and react to chemical molecules released by a desired cell or its surrounding area.
1486:"The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers"
1666:
893:"Directed transport of bacteria-based drug delivery vehicles: bacterial chemotaxis dominates particle shape"
1627:
1332:
1279:"Neutrophil chemotaxis in linear and complex gradients of interleukin-8 formed in a microfabricated device"
113:
109:
66:
16:
1646:
1021:"Mathematical modelling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites"
1228:
1497:
1032:
777:
1458:
1656:
1440:
1314:
1056:
1020:
996:
928:
864:
809:
697:
567:
540:
442:
1362:
1108:
Butler, K. S.; Durfee, P. N.; Theron, C.; Ashley, C. E.; Carnes, E. C.; Brinker, C. J. (2016).
957:"Microdroplets in Microfluidics: An Evolving Platform for Discoveries in Chemistry and Biology"
1603:
1595:
1531:
1513:
1432:
1424:
1306:
1298:
1256:
1248:
1139:
1048:
988:
920:
912:
856:
848:
801:
793:
746:
689:
681:
635:
617:
532:
434:
382:
364:
308:
1404:
661:
1587:
1521:
1505:
1416:
1290:
1240:
1129:
1121:
1040:
978:
968:
904:
840:
785:
736:
728:
673:
625:
609:
522:
424:
372:
354:
298:
1631:
1575:
579:
25:
1501:
1036:
781:
343:"Mimic Nature Using Chemotaxis of Ionic Liquid Microdroplets for Drug Delivery Purposes"
287:"Chemotaxis Model for Drug Delivery Using Turing's Instability and Non-Linear Diffusion"
1526:
1485:
1134:
741:
716:
630:
597:
377:
342:
29:
1640:
1444:
932:
892:
732:
701:
544:
136:
The applications of chemotactic drug delivery systems include but are not limited to
87:
20:
1318:
1000:
868:
446:
1060:
891:
Sahari, Ali; Traore, Mahama A.; Scharf, Birgit E.; Behkam, Bahareh (October 2014).
813:
158:
527:
510:
1244:
1392:. Institute for Quality and Efficiency in Health Care (IQWiG). 22 February 2018.
1387:
717:"Targeting the chemotactic function of CD147 reduces collagen-induced arthritis"
1044:
1591:
908:
662:"A Universal Chemotactic Targeted Delivery Strategy for Inflammatory Diseases"
429:
412:
359:
285:
Almijalli, Mohammed; Ibrahim, Moustafa; Saad, Ali; Saad, Mazen (28 May 2021).
117:
61:
57:
52:
1599:
1517:
1428:
1302:
1252:
916:
852:
828:
797:
685:
621:
438:
368:
312:
596:
Roussos, Evanthia T.; Condeelis, John S.; Patsialou, Antonia (August 2011).
1607:
1535:
1436:
1420:
1310:
1260:
1143:
1125:
1052:
992:
973:
956:
924:
750:
693:
677:
639:
536:
386:
1405:"Self-Propelled Micro/Nanomotors for Tumor Targeting Delivery and Therapy"
860:
805:
1278:
1172:"Enzyme-coated protocells could be used as targeted drug-delivery system"
844:
303:
286:
765:
983:
1509:
137:
1019:
Owen, Markus R.; Byrne, Helen M.; Lewis, Claire E. (February 2004).
613:
1294:
789:
1403:
Lin, Ruyi; Yu, Wenqi; Chen, Xianchun; Gao, Huile (January 2021).
1624:
558:
Láng, O.; Török, K.; Mező, G.; Hudecz F.; Kőhidai, L. (2003).
1227:
Alvarez-Lorenzo, Carmen; Concheiro, Angel (1 December 2013).
1079:"Artificial Cells Engineered to Act More Like the Real Thing"
1459:"Inflammation: What Is It, Causes, Symptoms & Treatment"
511:"Targeted drug delivery therapies inspired by natural taxes"
35:
341:
Khodarahmian, Kobra; Ghiasvand, Alireza (25 January 2022).
1235:. Chemical biotechnology • Pharmaceutical biotechnology.
827:
D'Souza, M. Patricia; Harden, Victoria (December 1996).
170:
Advantages and limitations of
Chemotactic Drug Targeting
47:
Importance of
Chemotaxis in Chemotactic Drug-Targeting
1574:
Kline, Daniel L.; Cliffton, Eugene E. (August 1952).
560:
Chemotactic conjugates New
Aspects in Drug-Targeting
1200:"4 Innovations in Nanoscale Drug Delivery - ASME"
413:"Chemical robotics — chemotactic drug carriers"
509:Nguyen, Hung V.; Faivre, Vincent (June 2020).
8:
1367:Centers for Disease Control and Prevention
132:Applications of Chemotactic Drug Targeting
1525:
1133:
982:
972:
740:
629:
526:
428:
376:
358:
302:
961:Angewandte Chemie International Edition
829:"Chemokines and HIV–1 second receptors"
272:
229:Biological and Bio-hybrid drug carriers
104:Biological and Bio-hybrid drug carriers
1356:
1354:
1272:
1270:
1222:
1220:
1194:
1192:
1166:
1164:
1162:
1160:
1103:
1101:
1099:
1072:
1070:
1014:
1012:
1010:
950:
948:
946:
944:
942:
575:
565:
28:character could be expended, however,
886:
884:
882:
880:
878:
504:
502:
500:
498:
496:
494:
492:
490:
488:
486:
484:
482:
480:
478:
476:
7:
655:
653:
651:
649:
591:
589:
474:
472:
470:
468:
466:
464:
462:
460:
458:
456:
406:
404:
402:
400:
398:
396:
336:
334:
332:
330:
328:
326:
324:
322:
280:
278:
276:
1229:"Bioinspired drug delivery systems"
766:"Chemokines and leukocyte traffic"
73:Chemotactic Drug Targeting Systems
14:
1550:"Choose your library affiliation"
1110:"Choose your library affiliation"
1233:Current Opinion in Biotechnology
764:Baggiolini, Marco (April 1998).
733:10.1111/j.1365-2567.2008.02877.x
86:Recent progress in the field of
1576:"Lifespan of Leucocytes in Man"
1361:CDCBreastCancer (12 May 2021).
1077:State, Penn (7 December 2019).
411:Lagzi, István (1 August 2013).
1176:European Pharmaceutical Review
1025:Journal of Theoretical Biology
1:
1580:Journal of Applied Physiology
1409:Advanced Healthcare Materials
528:10.1016/j.jconrel.2020.04.005
515:Journal of Controlled Release
1245:10.1016/j.copbio.2013.02.013
1683:
1045:10.1016/j.jtbi.2003.09.004
41:Chemotactic drug-targeting
1592:10.1152/jappl.1952.5.2.79
909:10.1007/s10544-014-9876-y
430:10.2478/s11536-012-0130-9
360:10.3390/molecules27030786
116:drug carriers is that of
1389:What is an inflammation?
897:Biomedical Microdevices
1421:10.1002/adhm.202001212
1126:10.1002/smll.201502119
974:10.1002/anie.200906653
678:10.1002/adma.202206654
598:"Chemotaxis in cancer"
67:targeted drug delivery
43:
17:Targeted drug delivery
602:Nature Reviews Cancer
39:
1630:30 July 2014 at the
1283:Nature Biotechnology
1662:Signal transduction
1502:2011NatMa..10..389A
1363:"Cancer Treatments"
1037:2004JThBi.226..377O
845:10.1038/nm1296-1293
782:1998Natur.392..565B
304:10.3390/app11114979
1554:docs.shib.ncsu.edu
666:Advanced Materials
51:In general terms,
44:
1339:. 2 February 2011
1120:(16): 2173–2185.
967:(34): 5846–5868.
839:(12): 1293–1300.
776:(6676): 565–568.
1674:
1652:Pharmacokinetics
1612:
1611:
1571:
1565:
1564:
1562:
1560:
1546:
1540:
1539:
1529:
1510:10.1038/nmat2992
1490:Nature Materials
1480:
1474:
1473:
1471:
1469:
1463:Cleveland Clinic
1455:
1449:
1448:
1400:
1394:
1393:
1384:
1378:
1377:
1375:
1373:
1358:
1349:
1348:
1346:
1344:
1329:
1323:
1322:
1274:
1265:
1264:
1239:(6): 1167–1173.
1224:
1215:
1214:
1212:
1210:
1196:
1187:
1186:
1184:
1182:
1168:
1155:
1154:
1152:
1150:
1137:
1105:
1094:
1093:
1091:
1089:
1074:
1065:
1064:
1016:
1005:
1004:
986:
976:
952:
937:
936:
888:
873:
872:
824:
818:
817:
761:
755:
754:
744:
712:
706:
705:
657:
644:
643:
633:
593:
584:
583:
577:
573:
571:
563:
555:
549:
548:
530:
506:
451:
450:
432:
408:
391:
390:
380:
362:
338:
317:
316:
306:
291:Applied Sciences
282:
1682:
1681:
1677:
1676:
1675:
1673:
1672:
1671:
1667:Taxes (biology)
1637:
1636:
1632:Wayback Machine
1621:
1616:
1615:
1573:
1572:
1568:
1558:
1556:
1548:
1547:
1543:
1482:
1481:
1477:
1467:
1465:
1457:
1456:
1452:
1402:
1401:
1397:
1386:
1385:
1381:
1371:
1369:
1360:
1359:
1352:
1342:
1340:
1331:
1330:
1326:
1276:
1275:
1268:
1226:
1225:
1218:
1208:
1206:
1198:
1197:
1190:
1180:
1178:
1170:
1169:
1158:
1148:
1146:
1107:
1106:
1097:
1087:
1085:
1076:
1075:
1068:
1018:
1017:
1008:
954:
953:
940:
890:
889:
876:
833:Nature Medicine
826:
825:
821:
763:
762:
758:
714:
713:
709:
672:(47): 2206654.
659:
658:
647:
614:10.1038/nrc3078
595:
594:
587:
574:
564:
557:
556:
552:
508:
507:
454:
410:
409:
394:
340:
339:
320:
284:
283:
274:
269:
256:
231:
206:
181:
172:
156:
147:
134:
106:
97:
84:
75:
49:
42:
26:chemoattractant
12:
11:
5:
1680:
1678:
1670:
1669:
1664:
1659:
1654:
1649:
1639:
1638:
1635:
1634:
1620:
1619:External links
1617:
1614:
1613:
1566:
1541:
1496:(5): 389–397.
1475:
1450:
1415:(1): 2001212.
1395:
1379:
1350:
1324:
1295:10.1038/nbt712
1289:(8): 826–830.
1266:
1216:
1188:
1156:
1095:
1066:
1031:(4): 377–391.
1006:
938:
903:(5): 717–725.
874:
819:
756:
707:
645:
608:(8): 573–587.
585:
562:. p. 118.
550:
452:
423:(4): 377–382.
392:
318:
271:
270:
268:
265:
255:
252:
251:
250:
249:
248:
241:
240:
239:
230:
227:
226:
225:
224:
223:
216:
215:
214:
205:
202:
201:
200:
199:
198:
191:
190:
189:
180:
177:
171:
168:
155:
152:
146:
143:
133:
130:
110:microorganisms
105:
102:
96:
93:
83:
80:
74:
71:
48:
45:
40:
30:chemorepellent
13:
10:
9:
6:
4:
3:
2:
1679:
1668:
1665:
1663:
1660:
1658:
1655:
1653:
1650:
1648:
1645:
1644:
1642:
1633:
1629:
1626:
1623:
1622:
1618:
1609:
1605:
1601:
1597:
1593:
1589:
1585:
1581:
1577:
1570:
1567:
1555:
1551:
1545:
1542:
1537:
1533:
1528:
1523:
1519:
1515:
1511:
1507:
1503:
1499:
1495:
1491:
1487:
1479:
1476:
1464:
1460:
1454:
1451:
1446:
1442:
1438:
1434:
1430:
1426:
1422:
1418:
1414:
1410:
1406:
1399:
1396:
1391:
1390:
1383:
1380:
1368:
1364:
1357:
1355:
1351:
1338:
1334:
1328:
1325:
1320:
1316:
1312:
1308:
1304:
1300:
1296:
1292:
1288:
1284:
1280:
1273:
1271:
1267:
1262:
1258:
1254:
1250:
1246:
1242:
1238:
1234:
1230:
1223:
1221:
1217:
1205:
1201:
1195:
1193:
1189:
1177:
1173:
1167:
1165:
1163:
1161:
1157:
1145:
1141:
1136:
1131:
1127:
1123:
1119:
1115:
1111:
1104:
1102:
1100:
1096:
1084:
1080:
1073:
1071:
1067:
1062:
1058:
1054:
1050:
1046:
1042:
1038:
1034:
1030:
1026:
1022:
1015:
1013:
1011:
1007:
1002:
998:
994:
990:
985:
980:
975:
970:
966:
962:
958:
951:
949:
947:
945:
943:
939:
934:
930:
926:
922:
918:
914:
910:
906:
902:
898:
894:
887:
885:
883:
881:
879:
875:
870:
866:
862:
858:
854:
850:
846:
842:
838:
834:
830:
823:
820:
815:
811:
807:
803:
799:
795:
791:
790:10.1038/33340
787:
783:
779:
775:
771:
767:
760:
757:
752:
748:
743:
738:
734:
730:
726:
722:
718:
711:
708:
703:
699:
695:
691:
687:
683:
679:
675:
671:
667:
663:
656:
654:
652:
650:
646:
641:
637:
632:
627:
623:
619:
615:
611:
607:
603:
599:
592:
590:
586:
581:
569:
561:
554:
551:
546:
542:
538:
534:
529:
524:
520:
516:
512:
505:
503:
501:
499:
497:
495:
493:
491:
489:
487:
485:
483:
481:
479:
477:
475:
473:
471:
469:
467:
465:
463:
461:
459:
457:
453:
448:
444:
440:
436:
431:
426:
422:
418:
417:Open Medicine
414:
407:
405:
403:
401:
399:
397:
393:
388:
384:
379:
374:
370:
366:
361:
356:
352:
348:
344:
337:
335:
333:
331:
329:
327:
325:
323:
319:
314:
310:
305:
300:
296:
292:
288:
281:
279:
277:
273:
266:
264:
260:
253:
245:
244:
242:
236:
235:
233:
232:
228:
220:
219:
217:
211:
210:
208:
207:
203:
195:
194:
192:
186:
185:
183:
182:
179:Microdroplets
178:
176:
169:
167:
163:
160:
153:
151:
144:
142:
139:
131:
129:
125:
121:
119:
115:
111:
103:
101:
94:
92:
89:
88:microfluidics
82:Microdroplets
81:
79:
72:
70:
68:
63:
59:
56:many toxins.
54:
46:
38:
34:
31:
27:
22:
21:drug delivery
18:
1647:Cell biology
1586:(2): 79–84.
1583:
1579:
1569:
1557:. Retrieved
1553:
1544:
1493:
1489:
1478:
1466:. Retrieved
1462:
1453:
1412:
1408:
1398:
1388:
1382:
1370:. Retrieved
1366:
1341:. Retrieved
1336:
1327:
1286:
1282:
1236:
1232:
1207:. Retrieved
1204:www.asme.org
1203:
1179:. Retrieved
1175:
1147:. Retrieved
1117:
1113:
1086:. Retrieved
1083:SciTechDaily
1082:
1028:
1024:
964:
960:
900:
896:
836:
832:
822:
773:
769:
759:
727:(1): 55–62.
724:
720:
710:
669:
665:
605:
601:
559:
553:
518:
514:
420:
416:
350:
346:
297:(11): 4979.
294:
290:
261:
257:
243:Limitations
218:Limitations
193:Limitations
173:
164:
159:Inflammation
157:
154:Inflammation
148:
135:
126:
122:
107:
98:
85:
76:
50:
15:
576:|work=
521:: 439–456.
234:Advantages
209:Advantages
184:Advantages
1657:Physiology
1641:Categories
1625:Chemotaxis
1337:cancer.gov
984:2066/83742
721:Immunology
353:(3): 786.
267:References
254:Conclusion
204:Protocells
118:chemotaxis
114:bio-hybrid
95:Protocells
62:chemotaxis
58:Chemotaxis
53:chemotaxis
1600:8750-7587
1518:1476-4660
1445:221915275
1429:2192-2640
1303:1546-1696
1253:0958-1669
933:254284178
917:1387-2176
853:1078-8956
798:0028-0836
702:252382827
686:0935-9648
622:1474-175X
578:ignored (
568:cite book
545:215411200
439:2391-5463
369:1420-3049
347:Molecules
313:2076-3417
1628:Archived
1608:12990547
1536:21499315
1437:32975892
1333:"cancer"
1319:11323479
1311:12091913
1261:23465754
1144:26780591
1053:14759644
1001:18609389
993:20572214
925:24907051
869:34538821
751:18557953
694:36122571
640:21779009
537:32259545
447:84150518
387:35164048
1559:7 April
1527:3287066
1498:Bibcode
1468:7 April
1372:7 April
1343:7 April
1209:7 April
1181:7 April
1149:7 April
1135:4964272
1088:7 April
1061:7990345
1033:Bibcode
861:8946819
814:4403366
806:9560152
778:Bibcode
742:2632695
631:4030706
378:8839142
1606:
1598:
1534:
1524:
1516:
1443:
1435:
1427:
1317:
1309:
1301:
1259:
1251:
1142:
1132:
1059:
1051:
999:
991:
931:
923:
915:
867:
859:
851:
812:
804:
796:
770:Nature
749:
739:
700:
692:
684:
638:
628:
620:
543:
535:
445:
437:
385:
375:
367:
311:
145:Cancer
138:cancer
1441:S2CID
1315:S2CID
1114:Small
1057:S2CID
997:S2CID
929:S2CID
865:S2CID
810:S2CID
698:S2CID
541:S2CID
443:S2CID
1604:PMID
1596:ISSN
1561:2023
1532:PMID
1514:ISSN
1470:2023
1433:PMID
1425:ISSN
1374:2023
1345:2023
1307:PMID
1299:ISSN
1257:PMID
1249:ISSN
1211:2023
1183:2023
1151:2023
1140:PMID
1090:2023
1049:PMID
989:PMID
921:PMID
913:ISSN
857:PMID
849:ISSN
802:PMID
794:ISSN
747:PMID
690:PMID
682:ISSN
636:PMID
618:ISSN
580:help
533:PMID
435:ISSN
383:PMID
365:ISSN
309:ISSN
1588:doi
1522:PMC
1506:doi
1417:doi
1291:doi
1241:doi
1130:PMC
1122:doi
1041:doi
1029:226
979:hdl
969:doi
905:doi
841:doi
786:doi
774:392
737:PMC
729:doi
725:126
674:doi
626:PMC
610:doi
523:doi
519:322
425:doi
373:PMC
355:doi
299:doi
1643::
1602:.
1594:.
1582:.
1578:.
1552:.
1530:.
1520:.
1512:.
1504:.
1494:10
1492:.
1488:.
1461:.
1439:.
1431:.
1423:.
1413:10
1411:.
1407:.
1365:.
1353:^
1335:.
1313:.
1305:.
1297:.
1287:20
1285:.
1281:.
1269:^
1255:.
1247:.
1237:24
1231:.
1219:^
1202:.
1191:^
1174:.
1159:^
1138:.
1128:.
1118:12
1116:.
1112:.
1098:^
1081:.
1069:^
1055:.
1047:.
1039:.
1027:.
1023:.
1009:^
995:.
987:.
977:.
965:49
963:.
959:.
941:^
927:.
919:.
911:.
901:16
899:.
895:.
877:^
863:.
855:.
847:.
835:.
831:.
808:.
800:.
792:.
784:.
772:.
768:.
745:.
735:.
723:.
719:.
696:.
688:.
680:.
670:34
668:.
664:.
648:^
634:.
624:.
616:.
606:11
604:.
600:.
588:^
572::
570:}}
566:{{
539:.
531:.
517:.
513:.
455:^
441:.
433:.
419:.
415:.
395:^
381:.
371:.
363:.
351:27
349:.
345:.
321:^
307:.
295:11
293:.
289:.
275:^
1610:.
1590::
1584:5
1563:.
1538:.
1508::
1500::
1472:.
1447:.
1419::
1376:.
1347:.
1321:.
1293::
1263:.
1243::
1213:.
1185:.
1153:.
1124::
1092:.
1063:.
1043::
1035::
1003:.
981::
971::
935:.
907::
871:.
843::
837:2
816:.
788::
780::
753:.
731::
704:.
676::
642:.
612::
582:)
547:.
525::
449:.
427::
421:8
389:.
357::
315:.
301::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
